

Onyx Biotec Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Balance Sheet as at March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

	Note	As at March 31, 2026	As at March 31, 2025
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	3	1,813.22	1,813.22
Reserves and surplus	4	3,727.56	3,749.00
		5,540.78	5,562.22
Non-current liabilities			
Long-term borrowings	5	468.94	675.67
Deferred tax liabilities (Net)	6	253.03	314.05
		721.97	989.73
Current liabilities			
Short-term borrowings	7	1,048.19	570.12
Trade payables	8		
i) Total outstanding dues of Micro & Small enterprises		163.83	95.85
ii) Total outstanding dues of creditors other than Micro & Small enterprises		1,600.80	1,577.29
Other current liabilities	9	289.88	229.39
Short-term provisions	10	150.00	100.19
		3,252.70	2,572.84
Total		9,515.46	9,124.79
ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible assets			
Property, Plant and Equipment	11	3,915.96	4,090.03
Capital work-in-progress		367.56	-
Other non current assets	12	104.11	115.94
		4,387.62	4,205.97
Current assets			
Inventories	13	1,403.96	1,609.99
Trade receivables	14	2,749.81	2,023.24
Cash and cash equivalents	15	403.74	861.21
Short term Loans and advances	16	77.39	17.45
Other current assets	17	492.93	406.92
		5,127.84	4,918.82
Total		9,515.46	9,124.79

Summary of significant accounting policies 2
The accompanying notes are an integral part of the financial statements

As per our report of even date

For R C A AND CO LLP
Chartered Accountants
Firm Registration No: 011602N/N500350

CA Mayank Bansal
Partner
Membership No: 550769
UDIN: 26550769KLXWSH2639
Place: Nalagarh
Date: 14 May 2026



For and on behalf of the Board of Directors of
Onyx Biotec Limited
CIN: L24230HP2005PLC028403

Sanjay Jain
Managing Director
DIN: 02214242

Harsh Mahajan
CEO & CFO
DIN: 09793917

Lakshya Jain
Whole Time Director
DIN: 09377707

Ruchi Chowdhury
Company Secretary



Onyx Biotec Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Statement of Profit and Loss for the period ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

	Note	Period ended March 31, 2026	Period ended March 31, 2025
TOTAL INCOME			
Revenue from operations	18	6,946.94	6,195.37
Other Income	19	44.46	116.51
		6,991.40	6,311.88
EXPENSES			
Cost of material consumed	20	5,111.57	3,860.51
(Increase)/decrease in stock-in-trade	21	53.71	52.63
Employee benefits expense	22	860.70	864.45
Depreciation, amortization & impairment expense	23	305.19	304.74
Finance costs	24	121.14	198.55
Other expenses	25	581.25	383.17
		7,033.57	5,664.06
Profit before prior period expenses and tax		(42.16)	647.82
Prior period expenses		0	0
Profit before tax		(42.16)	647.82
Tax (expense)/ credit:			
- Income tax expense		5.42	106.40
- Deferred tax charge		(61.02)	42.93
- Income tax expense (PY)		34.88	3.06
Total tax (expense)/ credit		-20.72	152.40
Profit for the year		-21.44	495.42
Basic and diluted earning per share		-0.12	3.31

[Nominal value of ₹ 10 each (previous year ₹ 10 each)]

Summary of significant accounting policies

2

The accompanying notes are an integral part of the financial statements

As per our report of even date

For R C A AND CO LLP
Chartered Accountants
Firm Registration No: 011602N/N500350

CA Mayank Bansal
Partner

Membership No: 550769
UDIN: 26550769KLXWSH2639

Place: Nalagarh
Date: 14 May 2026



For and on behalf of the Board of Directors of
Onyx Biotec Limited
CIN: L24230HP2005PLC028403

Sanjay Jain
Managing Director
DIN: 02214242

Harsh Mahajan
CEO & CFO
DIN : 09793917

Lakshya Jain
Whole Time Director
DIN : 09377707

Ruchi Chowdhury
Company Secretary



Onyx Biotec Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Cash Flow Statement for the period ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

	Period ended March 31, 2026	Period ended March 31, 2025
A Cash Flow from Operating activities		
Profit before tax	(42.16)	647.82
Adjustments for:		
Depreciation, amortization & impairment	305.19	304.74
Gain on sale of Fixed assets		(95.42)
Interest expenses	121.14	198.55
Interest income	(40.43)	(17.25)
Provision for gratuity (unfunded)	-	69.67
Operating cash flows before working capital changes	343.74	1,108.12
Adjustments for changes in working capital:		
Change in trade receivables	(726.57)	(485.96)
Change in loans and advances and other assets	(145.94)	(62.81)
Change in non current assets	11.83	(5.91)
Change in inventories	206.03	(699.68)
Change in Provisions	9.51	(106.26)
Change in trade payables	91.49	294.58
Change in other liabilities	60.49	99.62
Cash used in operations	(149.42)	141.70
Taxes paid (net of refund)	-	-
Net cash (used in) operating activities	(149.42)	141.70
B Cash flow from Investing activities		
Purchase of fixed assets including capital work in progress	(498.68)	(105.49)
Sale of fixed assets	-	153.86
Interest received	40.43	17.25
Net cash (used in) investing activities	(458.25)	65.62
C Cash flow from Financing activities		
Proceeds from issue of share capital including securities premium	-	2,538.02
Long term borrowings	(206.73)	(1,683.42)
Short term borrowings	478.08	(148.84)
Interest paid	(121.14)	(198.55)
Net cash flow from financing activities	150.20	507.21
Net (decrease) in cash and cash equivalents (A+B+C)	(457.47)	714.53
Cash and cash equivalents at the beginning of the year	861.21	146.68
Cash and cash equivalents at the end of the year	403.74	861.21
Cash and cash equivalents comprise (Refer note 17)		
Balances with banks		
-In current accounts	7.31	102.46
-Bank deposits with less than twelve months maturity	373.19	741.52
Cash in hand	23.24	17.24
	403.74	861.21

Notes :

1. The Cash Flow Statement has been prepared in accordance with the 'indirect method' set out in Accounting Standard-3, "Cash Flow Statement" notified under Section 133 of the Companies Act 2013, read together with Rule 7 of the Companies (Accounts) Rules
2. Figures in bracket indicate cash outflow.
3. The accompanying notes form an integral part of these financial statements.

As per our report of even date

For R C A AND CO LLP

Chartered Accountants

Firm Registration No: 011602N/N500350

CA Mayank Bansal

Partner

Membership No: 550769

UDIN: 26550769KLXWSH2639

Place: Nalagarh

Date: 14 May 2026



For and on behalf of the Board of Directors of

Onyx Biotec Limited

CIN: L24230HP2005PLC028403

Sanjay Jain

Managing Director

DIN: 02214242

Lakshya Jain

Whole Time Director

DIN : 09377707

Harsh Mahajan

CEO & CFO

DIN : 09793917

Ruchi Chowdhury

Company Secretary



Onyx Biotech Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

3 Share capital

The Company has only one class of share capital having a par value of ₹ 10 per share, referred to herein as equity shares.

Authorized

Equity shares of ₹ 10 each (Previous year ₹ 10 each)

Issued, subscribed and paid up

Equity shares of ₹ 10 each (Previous year ₹ 10 each)

Total

As at March 31, 2026		As at March 31, 2025	
Number	Amount	Number	Amount
2,00,00,000	2,000.00	2,00,00,000	2,000.00
1,81,32,200	1,813.22	1,81,32,200	1,813.22
1,81,32,200	1,813.22	1,81,32,200	1,813.22

Note

3.1 Reconciliation of shares outstanding at the beginning and at the end of the year

Particulars

Outstanding at the beginning of the year
Changes in equity share capital due to prior period errors
Balance at the beginning of the current reporting period
Add: Bonus shares issued during year
Add: Issued during the year
Outstanding at the end of the year

As at March 31, 2026		As at March 31, 2025	
Number	Amount	Number	Amount
1,81,32,200	1,813.22	1,33,22,200	1,332.22
1,81,32,200	1,813.22	1,33,22,200	1,332.22
-	-	48,10,000	481.00
1,81,32,200	1,813.22	1,81,32,200	1,813.22

3.2 Rights, preferences and restrictions attached to shares

Voting: Each shareholder is entitled to one vote per share held.

Dividend: The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to approval of the shareholders in the ensuing Annual General Meeting.

Liquidation: In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.

3.3 Shares held by promoter as the end of reporting year

Mr. Sanjay Jain
Mr. Naresh Mahajan
Mr. Fateh Pal Singh

As at March 31, 2026		As at March 31, 2025	
Number	Amount	Number	Amount
38,94,600	389.46	38,94,600	389.46
43,47,000	434.70	43,47,000	434.70
35,61,600	356.16	35,61,600	356.16
1,18,03,200	1,180.32	1,18,03,200	1,180.32

3.4 Details of shareholders holding more than 5% in the Company

Equity shares of ₹10 Each fully paid

Mr. Sanjay Jain
Mr. Naresh Mahajan
Mr. Fateh Pal Singh

As at March 31, 2026		As at March 31, 2025	
Number	% of holding	Number	% of holding
38,94,600	21.48%	38,94,600	21.48%
43,47,000	23.97%	43,47,000	23.97%
35,61,600	19.64%	35,61,600	19.64%
1,18,03,200	65.10%	1,18,03,200	65.10%

3.5 Shares reserved for issue under options and contracts/commitments for the sale of shares/disinvestment, including the terms and amounts : NIL

3.6 During the year, the Company, had completed the Initial Public Offering (IPO) of 48,10,000 Equity Shares of Face Value of Rs. 10 each for cash at a price of Rs.61 per Equity Share aggregating to Rs. 2934.10 Lakhs comprising a Fresh Issue of 48,10,000 Equity Shares aggregating to Rs. 2934.10 Lakhs. The approval for IPO was sought from the shareholders of the Company at their meeting held on 26-July-2024. The Equity Shares of the Company were listed on SME Platform of NSE Limited (NSE Emerge).

3.7 The details of utilization of IPO proceeds of Rs. 2934.10 lakhs are as follows:

Particulars

Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use
Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections
Prepayment or repayment of all or a portion of certain loans availed by our Company
General corporate purposes
Issue related expenses

Proceeds	Utilisation upto 31st March 2026	Unutilised upto 31st March 2026
607.70	433.54	607.70
124.05	91.55	124.05
1,200.00	1,200.00	1,200.00
606.27	599.42	606.27
396.08	396.08	396.08
2,934.10	2,720.59	2,934.10

* Unutilised amount of ₹ 206.66 lakhs have been invested/parked in fixed deposit with Kotak Mahindra Bank

*Unutilised amount of ₹ 6.85 lakhs have been separately kept in account created with HDFC Bank for IPO purpose.

[Handwritten signatures]



Onyx Biotec Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

	As at March 31, 2026	As at March 31, 2025
4 Reserves and surplus		
(a) Securities premium account		
Opening balance	2,269.68	212.66
Add: Securities premium credited on share issue	-	2,453.10
Less: Securities premium debited on Bonus Issue	-	-
Less: IPO expenses	-	-396.08
	<u>2,269.68</u>	<u>2,269.68</u>
(b) General Reserve		
Opening balance	1,479.33	983.91
Less) Bonus shares issued during year	-	-
Add: Net profit for the year	-21.44	495.42
	<u>1,457.88</u>	<u>1,479.33</u>
	<u>3,727.56</u>	<u>3,749.00</u>
5 Long term borrowings		
(a) Secured loan considered good		
Term loan from Bank	565.63	709.39
Less: Current Maturity	-142.62	-160.45
	<u>423.01</u>	<u>548.94</u>
(b) Unsecured loan considered good		
Loan from Related parties	45.93	126.73
	<u>45.93</u>	<u>126.73</u>
Total Long term borrowings	<u>468.94</u>	<u>675.67</u>
6 Deferred tax liabilities (Net)		
Deferred tax liabilities	253.03	314.05
	<u>253.03</u>	<u>314.05</u>
7 Short term borrowings		
(a) Secured borrowings		
Cash Credit Accounts	905.57	409.67
Current Maturity of long term borrowings	142.62	160.45
Total short term borrowings	<u>1,048.19</u>	<u>570.12</u>

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]



Onyx Biotec Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")

8 Trade payables	As at March 31, 2026	As at March 31, 2025
(a) Total outstanding dues to micro enterprises and small enterprises (Refer note)	163.83	95.85
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,600.80	1,577.29
	1,764.63	1,673.14

9 Other current liabilities	As at March 31, 2026	As at March 31, 2025
Other payables		
-Statutory liabilities	11.98	11.21
Employee related payables		
-Related Party	50.70	14.22
-Other parties	47.93	44.10
-Provision for expenses	61.18	66.43
-Provision for Gratuity	46.63	55.25
-Audit Fee payable	5.40	5.40
-Cheques issued but not presented	3.33	2.38
-Credit card dues	25.01	24.63
- Advance from Customers	37.72	5.79
	289.88	229.39

10 Short term Provisions	As at March 31, 2026	As at March 31, 2025
Provision for income taxes (net of advance tax and TDS)	-	100.19
Provision for doubtful debts	150.00	-
	150.00	100.19

[Handwritten signature]

[Handwritten signature]



Onyx Biotech Limited

(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")

CIN: L24230HP2005PLC028403

Notes to the financial statements for the year ended March 31, 2026

(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)


Note No. 5 and 7

As at 31st March, 2026

(A) Loan Schedule as at 31st March, 2026

Name of the Lender	Nature of Loan	Rate of Interest	Repayment Term	Balance at period end (Rs. In Lakhs)	Loan Financed (Rs. In Lakhs)	Description
HDFC Bank Limited	Cash Credit	Repo+2.73% per annum	On Demand	669.71	1,250.00	1) Mortgage (Collateral) : a. Security of Books Debts and stocks b. Industrial Property - Khewat/khatauni No. 18/18, Khasra No. 139/53, Village Teliwala, Nalagarh Khewat/khatauni No. 9/9, Khasra No. 140/53/1, Village Teliwala, Nalagarh, Himachal Pradesh Near Super Freeze Unit Nalagarh Himachal Pradesh 174101 c. Khatoni No. 187/206 Khasra No. 397/1 Tadadi 03 Bigha 1 Biswa & K/k Mouza Veer Plashi Tehsil Nalagarh Distt No. 164/169-170 1 Bigha 12 Biswa H.b No. 101 Ropar To Nalagarh Road Nalagarh Himachal Pradesh 174101
HDFC Bank Limited	Term Loan	Repo+2.55% per annum	48 Months	251.31	400.00	2) Personal Guarantee of: Sanjay Jain, Naresh Kumar, Paramjeet Kaur, Lakshya Jain, Harsh Mahajan
HDFC Bank Limited	Term Loan	Repo+2.61% per annum	84 Months	171.32	250.00	First Charge on Asset acquired under loan Lien on FDR amounting to INR 4130000
HDFC Bank Limited	Term Loan	Repo+2.69% per annum	84 Months	103.08	150.00	Personal Guarantee of Directors
Small Industries Development Bank of India	Term Loan	8.50% per annum	60 Months	11.21	165.20	First Charge on Asset acquired under loan Extension of Lien on FDR amounting to INR 4130000 Lien on FDR amounting to INR 1540000
Small Industries Development Bank of India	Term Loan	8.51% per annum	60 Months	6.81	61.36	Personal Guarantee of Directors
Kotak Mahindra Bank	Vehicle Loan	8.10% per annum	36 Months	21.44	22.00	Hypothecation of Vehicle
Kotak Mahindra Bank	Loan against OD	Repo+2.1% per annum	12 Months	235.89	327.00	Fixed deposit
HDFC Bank Limited	Vehicle Loan	8.20% per annum	48 Months	0.44	4.65	Hypothecation of Vehicle
Loan from Directors	Unsecured Loan	NA	36 Months	45.93	45.93	Unsecured
Total Financial Indebtness				1,517.14		

Handwritten signatures and initials:
 1. *Amrinder*
 2. *Naresh*
 3. *Sanjay*
 4. *Naresh*



As at 31st March, 2025

(A) Loan Schedule as at 31st March, 2025

Name of the Lender	Nature of Loan	Rate of Interest	Repayment Term	Balance at period end (Rs. In Lakhs)	Loan Financed (Rs. In Lakhs)	Description
HDFC Bank Limited	Term Loan	Repo+2.8% per annum	42 Months	4.46	80.77	1) Mortgage (Collateral) : a. Security of Books Debts and stocks b. Industrial Property - Khewat/khatauni No. 18/18, Khasra No. 139/53, Village Teliwala, Nalagarh Khewat/khatauni No. 9/9, Khasra No. 140/53/1, Village Teliwala, Nalagarh, Himachal Pradesh Near Super Freeze Unit Nalagarh Himachal Pradesh 174101
HDFC Bank Limited	Cash Credit	Repo+2.8% per annum	On Demand	409.67	500.00	c. Khatoni No.187/206 Khasra No.397/1 Tadadi 03 Bigha 1 Biswa & K/k Mouza Veer Plashi Tehsil Nalagarh Distt No.164/169-170 1 Bigha 12 Biswa H.b No.101 Ropar To Nalagarh Road Nalagarh Himachal Pradesh 174101
HDFC Bank Limited	Term Loan	Repo+2.8% per annum	48 Months	305.08	400.00	d. House No. 795 Sector 11 An Panchkula Near Main Road Panchkula Haryana 134109
HDFC Bank Limited	Term Loan	Repo+2.8% per annum	84 Months	204.36	250.00	e. Plot No. 322-p, H. No. 1195, Chandigarh Sector 18-c, Near Market Chandigarh-ch Chandigarh 160018
HDFC Bank Limited	Term Loan	Repo+2.8% per annum	84 Months	123.01	150.00	2) Personal Guarantee of: Sanjay Jain, Naresh Kumar, Paramjeet Kaur, Lakshya Jain, Harsh Mahajan, Ramesh Kumar, Meenu Jain
Small Industries Development Bank of India	Term Loan	8.50% per annum	60 Months	47.92	165.20	First Charge on Asset acquired under loan Lien on FDR amounting to INR 4130000 Personal Guarantee of Directors
Small Industries Development Bank of India	Term Loan	8.51% per annum	60 Months	20.45	61.36	First Charge on Asset acquired under loan Extension of Lien on FDR amounting to INR 4130000 Lien on FDR amounting to INR 1540000 Personal Guarantee of Directors
Axis Bank Limited	Vehicle Loan	8.40% per annum	36 Months	2.38	20.00	Hypothecation of Vehicle
HDFC Bank Limited	Vehicle Loan	8.20% per annum	48 Months	1.72	4.65	Hypothecation of Vehicle
Loan from Directors	Unsecured Loan	NA	36 Months	126.73	126.73	Unsecured
Total Financial Indebtness				1,245.78		

Immunus *Lagan* *Rachet*



Onyx Biotech Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

Note No. 8 : Trade Payables (Continued)

Trade Payables ageing schedule as on 31st March, 2026

Particulars	Outstanding for Following periods From due date of payments				
	Less Than 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
Micro and Small Enterprises	159.37	2.99	-	11.47	173.83
Others	1,495.77	9.52	83.73	1.77	1,590.80
Disputed Dues- Micro and Small Enterprises	-	-	-	-	-
Disputed Dues- Others	-	-	-	-	-
Total Trade Payables	1,655.15	12.52	83.73	13.24	1,764.63

Trade Payables ageing schedule as on 31st March, 2025

Particulars	Outstanding for Following periods From due date of payments				
	Less Than 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
Micro and Small Enterprises	95.69	0.07	-	-	95.76
Others	1,453.34	109.61	14.35	-	1,577.29
Disputed Dues- Micro and Small Enterprises	-	-	-	-	-
Disputed Dues- Others	-	-	-	-	-
Total Trade Payables	1,549.03	109.68	14.35	-	1,673.06

Handwritten signatures and initials in blue ink.



Onyx Biotech Limited

(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")

CIN: L24230HP2005PLC028403

Notes to the financial statements for the year ended March 31, 2026

(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

11 PROPERTY, PLANT AND EQUIPMENT

Schedule for the year ended March 31 2026

DESCRIPTION	Gross Block				Depreciation				Net Block	
	As At	Additions	Adjustment/	As At	As At	Depreciation	Adjustment/	As At	As At	As At
Property, plant and equipment (PPE)	1st April, 2025	During the year	Deduction during the year	31st March 2026	1st April, 2025	The Year	Deduction during the Year	31st March 2026	31st March 2026	31st March, 2025
Plant and machinery	3,589.23	91.72	-	3,680.94	1,154.00	187.13	-	1,341.13	2,339.81	2,435.23
Building	1,215.80	15.54	-	1,231.34	262.10	36.29	-	298.39	932.95	953.70
Furniture and Fixture	105.59	2.36	-	107.95	37.13	8.86	-	45.98	61.96	68.46
Computer & Printer	31.49	1.19	-	32.68	19.33	5.36	-	24.69	7.99	12.16
Laboratory Equipment	219.08	0.86	-	219.94	92.32	17.51	-	109.83	110.10	126.76
Electrical Installation & Equipment	296.32	-	-	296.32	123.33	21.79	-	145.12	151.21	173.00
Office Equipment	53.45	0.48	-	53.93	24.62	7.56	-	32.18	21.75	28.83
Vehicles	298.35	18.85	-	317.19	237.11	14.79	-	251.90	65.29	61.24
Books and periodicals	1.45	-	-	1.45	1.03	0.13	-	1.16	0.30	0.42
Fire and Safety Equipment	29.70	-	-	29.70	4.33	1.55	-	5.89	23.81	25.36
CCTV CAMERAS	27.84	0.12	-	27.96	11.70	4.21	-	15.91	12.05	16.14
Land	188.73	-	-	188.73	-	-	-	-	188.73	188.73
Total	6,057.02	131.12	0.00	6,188.14	1,967.00	305.19	0.00	2,272.18	3,915.96	4,090.03
PY	6,013.89	105.49	-62.35	6,057.02	1,666.17	304.74	-3.91	1,967.00	4,090.03	4,347.72

Handwritten signatures and initials:
 Karan, Ruchi, and others.



Onyx Biotech Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

12 Other non current assets	As at March 31, 2026	As at March 31, 2025
Bank deposits with more than twelve months maturity	72.43	68.16
Security deposits	31.68	47.78
	104.11	115.94

13 Inventories	As at March 31, 2026	As at March 31, 2025
Finished Goods	51.73	105.44
Work-in progress	686.34	780.92
Raw Materials	345.71	464.57
Consumable stores	320.19	259.07
	1,403.96	1,609.99

14 Trade receivables	As at March 31, 2026	As at March 31, 2025
Trade receivables - unsecured(less than six months from the date they are due for payment)		
Considered good		
Related parties	-	-
Others	1,232.14	807.98
Trade receivables - unsecured(exceeding six months from the date they are due for payment)		
Considered good		
Related parties	-	-
Others	1,227.95	1,215.26
Significant increase in credit risk		
Related parties	-	-
Others	289.73	-
	2,749.81	2,023.24

[Handwritten signatures and initials in blue ink]



Onyx Biotech Limited

(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")

CIN: L24230HP2005PLC028403

Notes to the financial statements for the year ended March 31, 2026

(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

15 Cash and cash equivalents**Balances with banks:**

- In current accounts
- Bank deposits with less than twelve months maturity
- Cash in hand

As at March 31, 2026	As at March 31, 2025
7.31	102.46
373.19	741.52
23.24	17.24
403.74	861.21

16 Short term loans and advances**Unsecured, considered good**

Others

- Advance to Employees
- Advances to suppliers

As at March 31, 2026	As at March 31, 2025
-	5.13
77.39	12.32
77.39	17.45

17 Other current assets

- Prepaid expenses
- TDS recoverable (Net of provision for taxes)
- Balance with Revenue Authorities

As at March 31, 2026	As at March 31, 2025
12.98	19.73
5.22	
474.73	387.19
492.93	406.92

[Handwritten signatures]

[Handwritten signature]



Onyx Biotech Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

Note 14 : Trade Receivables (Continued)

Trade Receivables ageing schedule as on 31st March, 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Less Than 6 Months	6 Months-1 Year	1-2 Years	2-3 Years	More Than 3 Years	
Undisputed trade receivable-considered good	1,232.14	449.21	740.17	25.88	-	2,447.40
Undisputed trade receivable-which have significant increase in credit risk	-	-	-	-	-	-
Undisputed trade receivable-credit impaired	-	-	-	-	-	-
Disputed trade receivable -considered good	-	-	12.68	-	-	12.68
Disputed trade receivable -which have significant increase in credit risk	-	-	-	285.10	4.63	289.73
Disputed trade receivable-credit impaired	-	-	-	-	-	-
Total	1,232.14	449.21	752.85	310.98	4.63	2,749.81

Trade Receivables ageing schedule as on 31st March, 2025

Particulars	Outstanding for following periods from due date of payment					Total
	Less Than 6 Months	6 Months-1 Year	1-2 Years	2-3 Years	More Than 3 Years	
Undisputed trade receivable-considered good	1,585.28	110.95	326.90	0.12	-	2,023.24
Undisputed trade receivable-which have significant increase in credit risk	-	-	-	-	-	-
Undisputed trade receivable-credit impaired	-	-	-	-	-	-
Disputed trade receivable -considered good	-	-	-	-	-	-
Disputed trade receivable -which have significant increase in credit risk	-	-	-	-	-	-
Disputed trade receivable-credit impaired	-	-	-	-	-	-
Total	1,585.28	110.95	326.90	0.12	-	2,023.24

[Handwritten signatures]

Ruchit



Onyx Biotec Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403

Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

18 Revenue from operations

	Period ended March 31, 2026	Period ended March 31, 2025
Sale of finished products	6,788.88	6,175.32
Other operating revenues	92.45	-
Job Work Income	55.18	11.35
Testing and other charges	10.43	8.71
Sale of Scrap		
	6,946.94	6,195.37

19 Other income

	Period ended March 31, 2026	Period ended March 31, 2025
Interest income	40.43	17.25
- fixed deposit	2.16	1.94
Miscellaneous Income	1.87	1.51
Freight Income	-	0.40
Rent Income	-	95.42
Profit on sale of building		
	44.46	116.51

20 Cost of material consumed

	Period ended March 31, 2026	Period ended March 31, 2025
Cost of material consumed	5,111.57	3,860.51
	5,111.57	3,860.51

21 (Increase)/decrease in finished goods

	Period ended March 31, 2026	Period ended March 31, 2025
Opening Stock	105.44	158.07
Less: Closing stock	51.73	105.44
	53.71	52.63

22 Employee benefits expense

	Period ended March 31, 2026	Period ended March 31, 2025
Salaries, wages bonus and other allowances	792.29	726.51
Contribution to provident and other funds	41.94	44.70
Gratuity expenses	2.13	69.67
Staff welfare expenses	24.35	23.56
	860.70	864.45



Handwritten signatures and initials in blue ink.

Onyx Biotec Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403

23 Depreciation and amortization expense

Depreciation of tangible assets (Refer note 11)

Period ended March 31, 2026	Period ended March 31, 2025
305.19	304.74
305.19	304.74

24 Finance cost

Interest expense
 -Borrowing cost

Period ended March 31, 2026	Period ended March 31, 2025
121.14	198.55
121.14	198.55

25 Other Expenses

Freight outward
 Repairs and maintenance - Machinery
 Repairs and maintenance - Others
 Rates fee and taxes
 Donation
 Travelling
 Vehicle running expenses
 Plant Cleaning & Audit Expenses
 CSR Expenditure
 Provision for doubtful debts
 Legal and professional
 Auditor's remuneration (Refer note 26)
 Business promotion
 Office expenses
 Insurance expenses
 Interest and Penalty for delay in payment
 Rent of Machinery
 Printing & Stationery
 Postage and Courier Charges
 Telephone expenses
 Bank charges
 Security contract charges
 Software expenses
 Validation Testing & Calibration charges
 Miscellaneous expense

Period ended March 31, 2026	Period ended March 31, 2025
119.39	116.35
82.46	72.16
28.01	24.37
9.35	9.40
0.21	0.17
2.09	10.23
29.33	27.83
16.01	8.00
11.20	-
150.00	-
12.71	18.14
6.00	6.00
15.26	0.56
2.42	9.47
21.61	18.72
0.12	0.75
1.17	1.28
15.59	11.80
1.11	0.65
2.85	2.75
0.94	2.24
18.61	15.06
1.30	1.61
12.26	3.27
21.25	22.36
581.25	383.17

26 Payment to auditors (excluding applicable taxes)

Statutory audit
 Tax audit

Period ended March 31, 2026	Period ended March 31, 2025
5.50	5.50
0.50	0.50
6.00	6.00



[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

Onyx Biotech Limited
 (Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
 CIN: L24230HP2005PLC028403
 Notes to the financial statements for the year ended March 31, 2026
 (All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

27 Contingent Liabilities and Capital commitments

31st March, 2026

31st March, 2025

A) CAPITAL COMMITMENTS

Estimated amount of contracts remaining to be executed on capital account and not provided for (net of Other commitments relating to settlement of litigation disputes)

-
-

-
-

B) CONTINGENT LIABILITIES

There are no contingent liabilities as on the respective reporting periods.

28 Disclosure pursuant to Accounting Standard - 15 'Employee Benefits' as notified u/s 133 of the Companies Act, 2013

The following are the types of defined benefit plans:

a Gratuity Plan

15 days salary for every completed year of service. Vesting period is 5 years and payment is restricted to Rs. 20 lacs. The present value of defined obligation and related current cost are measured using the Projected Unit Credit Method with actuarial valuation being carried out at each balance sheet date.

Risk Exposure

Through its defined benefit plans, the company is exposed to a number of risks, the most significant of which are detailed below:


Interest Rates Risk	The defined benefit obligation calculated uses a discount rate based on government bonds. If bond yields fall, the defined benefit obligation will tend to increase. Thus the plan exposes the Company to the risk of fall in interest rates. Some times, the fall can be permanent, due to a paradigm shift in interest rate scenarios because of economic or fiscal reasons. A fall in interest rates will result in an increase in the ultimate cost of providing the above benefit and will thus result in an increase in the value of the liability (as shown in financial statements). Even for funded schemes, a paradigm downward shift in bond yields may
Salary Inflation Risk	The present value of the defined benefit plan is calculated with the assumption of salary escalation rate(SER), which is applied to find the salary of plan participants in future, at the time of separation Higher than expected increases in salary will increase the defined benefit obligation and will have an exponential effect.
Demographic Risk	Demographic assumptions are required to assess the timing and probability of a payment taking place. This is the risk of volatility of results due to unexpected nature of decrements that include mortality, attrition, disability and retirement. The effects of this decrement on the DBO depend upon the combination salary increase, discount rate, and vesting criteria and therefore not very straight forward. It is important not to overstate withdrawal rate because the cost of retirement benefit of a short serving
Actuarial Risk	It is the risk that benefits will cost more than expected. This can arise due to one of the following reasons: Adverse Salary Growth Experience: Salary hikes that are higher than the assumed salary escalation will result into an increase in Obligation at a rate that is higher than expected. Variability in mortality rates: If actual mortality rates are higher than assumed mortality rate assumption than the Gratuity

[Signature]

[Signature]

[Signature]

[Signature]



	benefits will be paid earlier than expected. Since there is no condition of vesting on the death benefit, the acceleration of cash
Liquidity Risk	This is the risk that the Company is not able to meet the short-term gratuity pay outs. This may arise due to non availability of enough cash / cash equivalent to meet the liabilities or holding of ill liquid assets not being sold in time.
Asset Liability Mismatch	This will come into play unless the funds are invested with a term of the assets replicating the term of the liability
Market Risk	Market risk is a collective term for risks that are related to the changes and fluctuations of the financial markets. One actuarial assumption that has a material effect is the discount rate. The discount rate reflects the time value of money. An increase in discount rate leads to decrease in Defined Benefit Obligation of the plan benefits & vice versa. This assumption depends on the yields on the corporate / government bonds and hence the valuation of liability is exposed to fluctuations in the yields as at the
Legislative Risk/Regulatory Risk	Legislative risk is the risk of increase in the plan liabilities or reduction in the plan assets due to change in the legislation / regulation. The government may amend the Payment of Gratuity Act thus requiring the companies to pay higher benefits to the employees. This will directly affect the present value of the Defined Benefit Obligation. The new labour code is a case in point. And the same will have to be recognized immediately in the year when any such amendment is effective.

c **Reconciliation of the net defined benefit (asset)/ liability**

The following table shows a reconciliation from the opening balances to the closing balances for the net defined benefit (asset)/ liability and its components:

Particulars	Gratuity	Leave Encashment	Gratuity	Leave Encashment
	March 31, 2026	March 31, 2026	March 31, 2025	March 31, 2025
Balance for previous years recorded in this year	55.24	6.38	43.69	2.98
Current Service Cost	9.65	3.35	25.98	3.40
Interest Cost on Defined Benefit Obligation	3.88	0.44	-	-
Current year Adjustments			-	-
Actuarial Gain and Losses arising from			-	-
Changes in demographic assumptions	-11.41	-1.25	-	-
Changes in financial assumptions			-	-
Experience Adjustment			-	-
Benefits Paid	-10.73	-1.63	-14.43	-
Balance at the end of the year	46.63	7.29	55.24	6.38

Note : No provision for gratuity or leave encashment was recorded in the earlier years..


Particulars	Gratuity	Leave Encashment	Gratuity	Leave Encashment
	March 31, 2026	March 31, 2026	March 31, 2025	March 31, 2025
Current Service Cost	9.65	3.35	25.98	3.40
Interest Cost	3.88	0.44	-	-
Actuarial Gain or Loss	(11.41)	(1.25)	-	-
Expenses recognized in Statement of Profit & Loss	2.13	2.54	25.98	3.40

Handwritten signature

Handwritten signature

Handwritten signature

Handwritten signature



e **Actuarial Assumptions**

Particulars	Gratuity	Leave Encashment	Gratuity	Leave Encashment
	March 31, 2026	March 31, 2026	March 31, 2025	March 31, 2025
Financial Assumptions				
Discount Rate	7.78%	7.78%	7.04%	7.04%
Salary Escalation Rate	5.50%	5.50%	5.50%	5.50%
Attrition Rates	10%	10%	10%	10%
Demographic Assumptions				
Mortality Rate	(100% of IALM (2012-14))	(100% of IALM (2012-14))	(100% of IALM (2012-14))	(100% of IALM (2012-14))
Disability Rate				
Withdrawal Rate	10%	10%	10%	10%
Note : Retirement Age 60				

f The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment

g **Sensitivity Analysis**

The sensitivity analyses below have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period. Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined

Particulars	Gratuity (31.03.2026)		
	% Increase in Defined Benefit Obligation	Liability	Increase / Decrease in Defined Benefit Obligations
Effect on DBO due to 0.5% increase in Discount Rate	-3.29%	45.10	(1.53)
Effect on DBO due to 0.5% decrease in Discount Rate	3.50%	48.26	1.63
Effect on DBO due to 0.5% increase in Salary Escalation Rate	3.56%	48.29	1.66
Effect on DBO due to 0.5% decrease in Salary Escalation Rate	-3.37%	45.06	(1.57)

Particulars	Gratuity (31.03.2025)		
	% Increase in Defined Benefit Obligation	Liability	Increase / Decrease in Defined Benefit Obligations
Effect on DBO due to 0.5% increase in Discount Rate	-3.45%	53.34	(1.91)
Effect on DBO due to 0.5% decrease in Discount Rate	3.68%	57.28	2.03
Effect on DBO due to 0.5% increase in Salary Escalation Rate	3.72%	57.30	2.06
Effect on DBO due to 0.5% decrease in Salary Escalation Rate	-3.51%	53.30	(1.94)

Handwritten signature

Handwritten signature

Handwritten signature

Handwritten signature



Particulars	Leave Encashment (31.03.2026)		
	% Increase in Defined Benefit Obligation	Liability	Increase / Decrease in Defined Benefit Obligations
Effect on DBO due to 0.5% increase in Discount Rate	-3.72%	7.02	(0.27)
Effect on DBO due to 0.5% decrease in Discount Rate	3.92%	7.58	0.29
Effect on DBO due to 0.5% increase in Salary Escalation Rate	4.01%	7.58	0.29
Effect on DBO due to 0.5% decrease in Salary Escalation Rate	-3.78%	7.01	(0.28)
Particulars	Leave Encashment (31.03.2025)		
	% Increase in Defined Benefit Obligation	Liability	Increase / Decrease in Defined Benefit Obligations
Effect on DBO due to 0.5% increase in Discount Rate	-3.84%	6.13	(0.25)
Effect on DBO due to 0.5% decrease in Discount Rate	4.04%	6.64	0.26
Effect on DBO due to 0.5% increase in Salary Escalation Rate	4.11%	6.64	0.26
Effect on DBO due to 0.5% decrease in Salary Escalation Rate	-3.87%	6.13	(0.25)

While one of the parameters mentioned above is changed by 50 basis points, Other parameters are kept unchanged for evaluating the DBO. Further, Sensitivities due to mortality & withdrawals have been considered as not material & hence impact of change due to these not calculated. Sensitivities as rate of increase of pensions in payment, rate of increase of pensions before retirement & life Although the analysis does not take account of the full distribution of cash flows expected under the plan, it does provide an approximation of the sensitivity of the assumptions shown.

29 Earnings per share (EPS) as per AS 20

31st March, 2026

31st March, 2025

Calculation of weighted average number of equity shares of Rs 10 each fully paid up:

Number of equity shares at the beginning of the year	1,81,32,200	1,33,22,200
Total number of equity shares outstanding at the end of the year-A	0	1,81,32,200
Weighted average number of equity shares outstanding during the year -B	1,81,32,200	1,49,81,128
Net profit attributable to equity shareholders for calculation of basic EPS - C	(21.44)	495.42
Basic and Diluted EPS (Rs.) (C/B)(Based on weighted average number of shares)	-0.12	3.31
Basic and Diluted EPS (Rs.) (C/A)(Based on shares at the end of year)	-0.12	2.73

30 Disclosure on Corporate Social Responsibility Expenses

Provisions of Section 135 of the Companies Act, 2013 and rules made thereunder are not applicable to the company.

[Handwritten signatures]

[Handwritten signature]



31 Segment Information

a) Identification of Operating Segments

The Company operates in a Single Reportable Primary Segment (Business Segment) i.e. Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup. No other operating segments have been aggregated to form the above reportable operating segments as per the criteria

b) Business Segment wise revenue/results/assets/liabilities

Since there is Single Reportable Operating Segment hence disclosure of Operating Segment wise Assets, Liabilities, Revenue and Results are not applicable.

32 Related party transactions

1) Name of the related parties irrespective of whether transactions have occurred or not :

a) Key management personnel ('KMP') and their relatives	Relation
Mr. Sanjay Jain	Managing Director
Mrs. Meenu Jain	Spouse of Promoter
Darshan Kumar Jain	Father of Promoter
Devinder Jain	Mother of Promoter
Mr. Lakshya Jain	Whole Time Director
Latika Jain	Daughter of Promoter
Mrs. Sanya Jain	Spouse of Director
Mr. Harsh Mahajan	CEO and CFO
Mr. Naresh Kumar	Whole Time Director
Mrs Anita Mahajan	Spouse of Promoter
Riya Mahajan	Daughter of Promoter
Muskaan Handa Mahajan	Spouse of Director
Late Mr. Sanjeev Pal Singh	Promoter
Fateh Pal Singh	Promoter
Paramjeet Kaur	Non-executive director
Mrs. Mehak Sood	Spouse of promoter
Mr. Marshal Ahluwalia	Brother of promoter
Mr. Harsh Jhunjhunwala	Company Secretary
Mrs. Ruchi Chowdhury	Company Secretary

b) Entities in which KMP and their relatives can exercise


Rosllion Healthcare Private Limited
S K Enterprises
Imperial India
M/s. Engineers Associate

Note: The name of the related party and their relationship with the Company is as identified by the management and relied upon by the auditors.

[Handwritten signatures]

[Handwritten signature]

[Handwritten signature]



II) Disclosure of Transaction between the Company and Related Party that has taken place during the year and its status of outstanding

A) Transactions with Key Managerial Personnel

Name of the party	Nature of Transactions	31st March, 2026	31st March, 2025
Mr. Sanjay Jain	Directors Remuneration	30.00	20.73
Mr. Naresh Kumar	Directors Remuneration	30.00	20.73
Mr. Lakshya Jain	Directors Remuneration	30.00	20.73
Mr. Harsh Mahajan	Directors Remuneration	30.00	20.73
Mrs. Mehak Sood	Salary	30.00	15.00
Mr. Harsh Jhunjhunwala	Salary	-	0.90
Mrs. Ruchi Chowdhury	Salary	1.82	-
Mr. Naresh Kumar	Loan Repayment	20.80	40.00
Smt. Parmjeet Kaur	Loan Repayment	20.00	60.00
Mr. Sanjay Jain	Loan Repayment	40.00	20.00

B) Transactions with enterprises where Key Management

Name of the party	Nature of Transactions	31st March, 2026	31st March, 2025
M/s Imperial India	Machinery repair and maintenance	3.77	19.57
M/s Imperial India	Sale of scrap	4.02	0.00

d) Balances at the year end

Name of the party	Nature of Transactions	31st March, 2026	31st March, 2025
M/s Imperial India	Amount Payable	0.04	7.28
Mr. Sanjay Jain	Unsecured Loan	14.00	54.00
Mr. Naresh Kumar	Unsecured Loan	11.39	32.19
Smt. Parmjeet Kaur	Unsecured Loan	13.59	33.59
Mr. Harsh Mahajan	Unsecured Loan	6.95	6.95
Mr. Harsh Mahajan	Salary payable	21.00	2.97
Mr. Lakshya Jain	Salary payable	2.10	2.34
Mrs. Mehak Sood	Salary payable	21.00	2.97
Mrs. Ruchi Chowdhury	Salary payable	0.15	-
Mr. Naresh Kumar	Salary payable	6.00	2.97
Mr. Sanjay Jain	Salary payable	2.10	2.97

[Handwritten signatures]

Ruchi

24/04/2026



33 Information under section 186(4) of the companies Act, 2013

a) Loans given during the FY 2025-26

	As at 31st March, 2026	Given	Realised	As at 31st March, 2025
Wholly owned subsidiaries	-	-	-	-
Others	-	-	-	-

b) Loans given during the FY 2024-25

	As at 31st March, 2025	Given	Realised	As at 31st March, 2024
Wholly owned subsidiaries	-	-	-	-
Others	-	-	-	-

c) Investment made

There are no investments made by the company.

d) Guarantee given

- | | |
|--|-----|
| i) To secure obligation of wholly owned subsidiaries | NIL |
| ii) To secure obligation of other related parties | NIL |

e) Security given

There is no security given during the year.

In the opinion of the Board of Directors and to the best of their knowledge and belief, the valuation on realisation of financial assets and other assets in the ordinary course of business would not be less than the amount at which they are stated in the financial statements.

34 Previous year figures have been regrouped/ reclassified, where necessary, to conform to this year's classification.

35 Foreign currency transactions

Expenditure in foreign currency (on accrual basis)

Particulars	31st March, 2026	31st March, 2025
Purchase of goods	-	-

Earning in foreign currency (on accrual basis)

Particulars	31st March, 2026	31st March, 2025
Revenue from Operations	5,23,288.00	-

[Handwritten signatures and initials]



Onyx Biotech Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

Note - 36

A) Ratio Analysis

Ratio	Numerator	Denominator	FY 2025-26	FY 2024-25	Variances	% Variance	Reason
Current ratio (in times)	Total current assets	Total current liabilities	1.58	1.91	-0.33	-17.46	Due to increase in current liabilities
Debt-equity ratio (in times)	Debt consists of borrowings and lease liabilities	Total Equity	0.27	0.22	0.05	24.46	Due to increase in borrowings
Debt service coverage ratio (in times)	Earning for Debt Service= Net Profit before taxes+ Non cash operating expenses+ Interest+Other non cash adjustments	Debt service = Interest payments+Principal repayments	1.45	0.57	0.88	154.42	Due to reduction in long term borrowings
Return on equity ratio	Profit for the year less Preference dividend (if any)	Average total equity	0.00	0.12	-0.12	-103.22	Due to low profit
Inventory turnover ratio (in times)	Revenue from operations	Average Inventory	4.61	4.92	-0.31	-6.30	Due to increase in revenue and decrease in inventory
Trade receivables turnover ratio (in times)	Revenue from operations	Average trade receivables	2.91	3.48	-0.57	-16.35	Due to increase in trade receivables
Trade payables turnover ratio (in times)	Cost of Purchases	Average trade payables	3.01	2.56	0.45	17.38	Due to increase in cost of purchases
Net Capital turnover ratio (in times)	Revenue from operations	Average working capital (i.e. Total current assets less total current liabilities)	3.29	4.07	-0.78	-19.13	Due to Increase in Working Capital
Net profit ratio (in %)	Profit for the year	Revenue from operations	-0.31%	8.00%	-8.31%	-103.86	Due to reduction in profit
Return on capital employed (in %)	Profit before tax and finance costs	Capital employed = Net worth + Lease liabilities+ Deferred tax	1.08%	11.88%	-10.80%	-90.91	Due to reduction in profit
Return on Investments (in %)	Income generated from invested funds	Average invested funds in treasury investments	NA	NA	NA	NA	NA

[Handwritten signatures and initials]



Onyx Biotech Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

Note 37 - RECONCILIATION OF QUARTERLY RETURN FILED BY COMPANY TO THE BANK AND BOOKS OF ACCOUNTS

Quarter	Particulars	Amount as per Statement Provided to bank (A)	Amount as per Books (B)	Difference (A-B)	Reason
Q1	Trade receivables	2,791.92	2,782.57	9.35	Please see note below
	Trade Payable	1,481.60	1,481.54	0.06	
	Stock	1,281.60	1,219.62	61.98	
	Total Revenue	1,792.51	1,792.51	0.00	
Quarter	Particulars	Amount as per Statement Provided to bank (A)	Amount as per Books (B)	Difference (A-B)	Reason
Q2	Trade receivables	2,743.22	2,680.43	62.79	Please see note below
	Trade Payable	1,259.21	1,429.99	(170.79)	
	Stock	1,326.63	1,204.58	122.05	
	Total Revenue	1,666.02	1,665.99	0.02	
Quarter	Particulars	Amount as per Statement Provided to bank (A)	Amount as per Books (B)	Difference (A-B)	Reason
Q3	Trade receivables	2,775.51	2,771.26	4.25	Please see note below
	Trade Payable	1,507.93	1,522.12	(14.19)	
	Stock	1,285.53	1,254.69	30.85	
	Total Revenue	1,799.73	1,802.30	(2.57)	
Quarter	Particulars	Amount as per Statement Provided to bank (A)	Amount as per Books (B)	Difference (A-B)	Reason
Q4	Trade receivables	2,717.65	2,749.81	(32.17)	Please see note below
	Trade Payable	1,751.89	1,764.63	(12.74)	
	Stock	1,484.33	1,403.96	80.37	
	Total Revenue	1,656.11	1,682.11	(26.00)	
Note					
Final data was not available with the Company regarding the credit note, debit note, grouping at the time of submitting DP statement to the bank. The Revenue and Trade receivable for the purpose of DP statement were calculated by the Company on the basis of data available at that time, however, the final entries were made later on, on the basis of which the books of accounts are reconciled and updated accordingly, because of which the actual figures as per books of accounts and as per DP statement varies. Also, valuation of inventories is done for the purpose of accounting in the books at a later date due to which there are variations in the inventory.					

Amrinder *Rajwan* *Harsh* *Ruchi*



Onyx Biotech Limited
(Formerly Known as "ONYX BIOTEC PRIVATE LIMITED")
CIN: L24230HP2005PLC028403
Notes to the financial statements for the year ended March 31, 2026
(All amounts are in Indian Rupees in Lakhs, unless otherwise stated)

NOTES 38
OTHER RELEVANT DISCLOSURES

Additional regulatory information required by Schedule III of Companies Act, 2013:

- A. The company do not have any Benami property, where any proceeding has been initiated or pending against the company for holding any Benami Property.
- B. Balance of Debtors & Creditors & Loans & advances Taken & giving are subject to confirmation and subject to consequential adjustments, if any. Debtors & creditors balance has been shown separately and the advances received and paid from/to the parties is shown as advance from customer and advance to suppliers.
- C. The company has no transactions, which are not recorded in the books of accounts and which are surrendered or disclosed as income during the year in the tax assessment or in search or survey or under any other relevant provision of the Income Tax Act, 1961.
- D. The Company has not traded or invested in crypto currency or virtual currency for the year ended March 2025 and March 2024.
- E. The Company do not had any transaction for the year ended March 2025 and March 2024 with the companies which are struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.
- F. The company has not been declared as willful defaulter by any bank or from any other lender for period ended March 2025 and March 2024.
- G. The company has registered all the charges which are required to be registered under the terms of the loan and liabilities and submitted Documents with ROC within the period as required by Companies Act, 2013.
- H. As per the information & detail available on records and the disclosure given by the management, the company has complied with the number of layers prescribed under clause (87) of section 2 of the companies act read with the Companies (Restriction on number of layers) Rules 2017.
- I. As per the Information & details available on records and the disclosure given by the management, the company has not advanced, loaned or invested to any other person or entity or foreign entities with the understanding that the intermediary shall directly or indirectly lend or invest in other person or entities identified in any manner whatsoever by or on behalf of the company or provided any guarantee, security or like to or on behalf of the company. Further the company has not received any funds from any person, entity including the foreign entity with the understanding that the company shall directly or indirectly lend, invest or guarantee, security or like manner on behalf of the funding party.
- J. Compliance with approved scheme(s) of arrangements: The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.
- K. The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017

For R C A AND CO LLP
Chartered Accountants
Firm Registration No: 011602N/NS00350

For and on behalf of the Board of Directors of
Onyx Biotech Limited
CIN: L24230HP2005PLC028403

CA Mayank Bansal
Partner
Membership No: 350769
UDIN: 26550769K1XWSH2639
Place: Nalagarh



Sanjay Jain
Managing Director
DIN: 02214242

Harsh Mahajan
CEO & CFO
DIN: 09793917

Lakshya Jain
Whole Time Director
DIN: 09377707

Ruchi Chowdhury
Company Secretary

